Research - Page 51 of 720 Posts on Medivizor
Navigation Menu

Research Posts on Medivizor

Will changing to a Mediterranean diet improve cholesterol in patients with coronary heart disease?

Will changing to a Mediterranean diet improve cholesterol in patients with coronary heart disease?

Posted by on Sep 5, 2021 in Coronary artery disease | 0 comments

In a nutshell This study compared the Mediterranean diet (MD) with the low-fat diet (LFD) in patients with coronary artery disease (CAD). It found that after 3 months the MD was associated with higher omega-3 levels than the LFD. Some background Cholesterol is the name commonly used for the fats in the blood. Cholesterol can block the...

Read More

Does radiotherapy increase the risk of heart disease in patients with Hodgkin lymphoma?

Does radiotherapy increase the risk of heart disease in patients with Hodgkin lymphoma?

Posted by on Sep 5, 2021 in Hodgkin's lymphoma | 0 comments

In a nutshell This study looked at the 30-year risk of heart disease in patients with Hodgkin lymphoma (HL) treated with radiotherapy. It found that radiotherapy led to a small increase in the risk of death from heart disease or stroke in these patients.  Some background HL is often treated with a combination of chemotherapy and...

Read More

Is closed-loop glucose control an effective treatment for patients with type 2 diabetes with serious kidney disease?

Is closed-loop glucose control an effective treatment for patients with type 2 diabetes with serious kidney disease?

Posted by on Sep 5, 2021 in Diabetes mellitus | 0 comments

In a nutshell This study looked at the use of closed-loop glucose control treatment for patients with type 2 diabetes (T2D) requiring dialysis. It found that compared to standard insulin therapy, closed-loop glucose control led to improved glucose control in these patients.  Some background Closed-loop glucose control is a form of insulin...

Read More

Evaluating the effectiveness and safety of triple combination therapy with immunotherapy and targeted therapy for patients with advanced-stage melanoma.

Evaluating the effectiveness and safety of triple combination therapy with immunotherapy and targeted therapy for patients with advanced-stage melanoma.

Posted by on Sep 5, 2021 in Melanoma | 0 comments

In a nutshell This study evaluated the effectiveness and safety of triple combination therapy with immune and targeted therapies in patients with stage III-IV melanoma. The data showed that triple combination therapy was associated with increased survival benefits with manageable side effects for these patients. Some background Melanoma is an...

Read More

Evaluating the impact of brain metastasis in the effectiveness of immunotherapy in patients with non-small cell lung cancer

Evaluating the impact of brain metastasis in the effectiveness of immunotherapy in patients with non-small cell lung cancer

Posted by on Sep 5, 2021 in Lung cancer | 0 comments

In a nutshell This study evaluated the effectiveness of immune checkpoint inhibitors (ICI) versus chemotherapy in patients with non-small cell lung cancer (NSCLC) andy brain metastases (BM). The data showed that the effectiveness of ICIs was similar in patients with no BM symptoms and/or treated BMs. For patients with BMs, ICI combination therapy was...

Read More

Evaluating the benefits of denosumab on bone health in women with early-stage breast cancer.

Evaluating the benefits of denosumab on bone health in women with early-stage breast cancer.

Posted by on Sep 5, 2021 in Breast cancer | 0 comments

In a nutshell This study evaluated the benefits of denosumab (Xgeva) on the bone health of women with early-stage breast cancer (BC). The data showed that denosumab improved bone-related outcomes in women with high-risk early-stage BC Some background BC is one of the most common forms of cancer in women. Early-stage BC is used to describe BC that is...

Read More

Selecting treatment regimen for newly diagnosed advanced stage follicular lymphoma.

Selecting treatment regimen for newly diagnosed advanced stage follicular lymphoma.

Posted by on Aug 29, 2021 in Non-Hodgkin lymphoma | 0 comments

In a nutshell The study evaluated the association of interleukin-2 (IL2) receptor (R) levels in the blood (a protein present on immune cells) in selecting a treatment for advanced-stage follicular lymphoma with a low tumor burden (FL-LTB). The study showed that patients with high IL-2R levels had better survival when treated with...

Read More

Evaluating the effects of various treatments on cognitive function in older men with resistant prostate cancer

Evaluating the effects of various treatments on cognitive function in older men with resistant prostate cancer

Posted by on Aug 29, 2021 in Prostate cancer | 0 comments

In a nutshell This study aimed to investigate the link between various treatments for castration-resistant prostate cancer (CRPC) and cognitive (mental) dysfunction in older men. The main finding was that the treatments assessed did not appear to have an impact on cognitive function. Some background CRPC is prostate cancer that keeps growing...

Read More

Comparing effectiveness and safety of acalabrutinib and ibrutinib in patients previously treated for chronic lymphocytic leukemia.

Comparing effectiveness and safety of acalabrutinib and ibrutinib in patients previously treated for chronic lymphocytic leukemia.

Posted by on Aug 29, 2021 in Leukemia | 0 comments

In a nutshell This study compared acalabrutinib (Calquence) and ibrutinib (Imbruvica) for the treatment of patients with chronic lymphocytic leukemia (CLL). The data showed that both drugs had similar effectiveness while acalabrutinib showed fewer cardiovascular side effects compared to ibrutinib. Some background Chronic lymphocytic...

Read More

Effects of nilotinib on height and safety in children with chronic myeloid leukemia.

Effects of nilotinib on height and safety in children with chronic myeloid leukemia.

Posted by on Aug 29, 2021 in Leukemia | 0 comments

In a nutshell This study assessed the safety and impact on the growth of nilotinib (Tasigna) in children with chronic myeloid leukemia (CML). The data indicated reduced growth rates with nilotinib treatment in children with CML. Some background Chronic myeloid leukemia (CML) is rare in children. However, it affects younger patients more...

Read More